Nouscom AG has appointed Eckhard Niemeier as chief business officer as the immuno-oncology company anticipates data read-outs from clinical trials in the next 12 months with its lead asset, NOUS-209. Nouscom is developing personalised neoantigen cancer immunotherapies. Its programmes include a randomised Phase 2 trial of NOUS-209 for the treatment of MSI solid tumours in combination with pembrolizumab.
Mr Niemeier joins Nouscom from UNION Therapeutics AS where he was CBO and previously held senior roles at Pieris Pharmaceuticals, Gruenenthal Pharma and MorphoSys. He holds a master’s degree in biotechnology.
Nouscom announced the appointment on 3 December 2024.
Copyright 2025 Evernow Publishing Ltd.